Delfi Krishna, Ph.D.
Vice President Late-Stage Development
Delfi Krishna joined Immatics in January 2021 and is responsible for the late-stage development of cell therapies.
Delfi has nearly 20 years of experience spanning from discovery to commercialization, contributing to the development of 15 biologics and 11 different cell therapies. During her Ph.D. at Georgia Institute of Technology, she designed efficient and targeted retroviral and lentiviral vectors for gene delivery in human cells. After completing her postdoctoral research, she joined GlaxoSmithKline, where she worked in biologics and cell therapy development.
At GlaxoSmithKline, she led large matrix teams to deliver process development, product strategy and regulatory submissions for several monoclonal antibodies, domain antibodies and antibody drug conjugates. She executed strategies to reduce costs while increasing speed and agility across all development phases, from pre-clinical through clinical proof of concept, launch and post launch. Delfi played a key role in shaping the technology, portfolio, organizational and talent strategy for the cell therapy business unit.
At Immatics, Delfi leads a cross functional medicine development team to bring autologous cell therapies to market. Delfi Krishna recently completed her MBA from MIT Sloan School of Management. Her leadership mission is to inspire colleagues to join her in bringing innovative medicines to patients while fostering an environment where individuals can reach their highest potential, find their most confident voice and have fun while breaking boundaries together.
In her free time, she likes to run science experiments with her daughter and dreams about doing T-cell experiments aboard the international space station.
Back
At GlaxoSmithKline, she led large matrix teams to deliver process development, product strategy and regulatory submissions for several monoclonal antibodies, domain antibodies and antibody drug conjugates. She executed strategies to reduce costs while increasing speed and agility across all development phases, from pre-clinical through clinical proof of concept, launch and post launch. Delfi played a key role in shaping the technology, portfolio, organizational and talent strategy for the cell therapy business unit.
At Immatics, Delfi leads a cross functional medicine development team to bring autologous cell therapies to market. Delfi Krishna recently completed her MBA from MIT Sloan School of Management. Her leadership mission is to inspire colleagues to join her in bringing innovative medicines to patients while fostering an environment where individuals can reach their highest potential, find their most confident voice and have fun while breaking boundaries together.
In her free time, she likes to run science experiments with her daughter and dreams about doing T-cell experiments aboard the international space station.